FDA panel dashes Merck’s hopes for broader use of Zetia, Vytorin

Tracy Staton In a blow for Merck & Co.'s cholesterol franchise, an FDA advisory panel shot down its bid to tout Vytorin and Zetia as preventives ...

What can Gilead, Biogen and Celgene teach Big Pharma about R&D?

John Carroll For the past 5 years the biopharma experts at Deloitte have been keeping an eye on a disturbing trend that shows no sign of letting up anytime soon. The biggest players ...

Novartis backs $176M microbiome biotech fund

John Carroll Novartis has stepped in to back Paris-based Seventure Partners' biotech fund focused exclusively on the emerging field of the microbiome as well as nutrition, bringing ...

Merck poised to win bigger market for cholesterol-fighting Zetia

Tracy Staton Merck & Co.'s cholesterol drug Zetia gets another day in the spotlight on Monday. An FDA advisory panel is debating results from an outcomes trial, Improve-It, ...

Wellcome invests $38M in another gene therapy startup, targeting hemophilia

Damian Garde The Wellcome Trust's investment arm is putting up £25 million ($ 38 million) to launch a new company developing a potential one-time treatment for hemophilia ...

UPDATED: Sanofi’s and Regeneron’s Praluent wins top billing on UnitedHealth Group’s formulary

Eric Palmer Sanofi and Regeneron's Praluent will be UnitedHealth Group's "preferred" drug for treating superhigh LDL cholesterol. The partners said that UnitedHealth ...

AstraZeneca bets on the future of the ‘secretome,’ joining a $100M research effort

Damian Garde AstraZeneca, on the hunt for new drug targets, is teaming up with a Swedish research outfit to explore the potential of an emerging class of proteins, joining a $ 100 ...

Discount sways U.K. cost gatekeeper on AstraZeneca’s ovarian cancer med Lynparza

Emily Wasserman AstraZeneca scored a victory for its ovarian cancer drug Lynparza, as U.K. cost watchdog the National Institute for Health and Care Excellence did an about-face and ...

Bayer looks to bone up in oncology after slipping behind rivals

Damian Garde German pharma giant Bayer is playing catch-up in the field of cancer treatments, expanding its efforts in hopes of cutting in on the burgeoning oncology market. FierceBiotech ...

Horizon shells out $510M for access to gout med Kyrstexxa

Carly Helfand Horizon may have quit on its hostile pursuit of California's Depomed, but that doesn't mean it's quit on dealmaking altogether. On the contrary, on Friday ...

Lilly and Merck pair ‘breakthrough’ therapies in latest cancer collaboration

Damian Garde Eli Lilly and Merck are expanding their oncology partnership to study a combination of the former's top cancer prospect with the latter's blockbuster immunotherapy. FierceBiotech ...

Shire and longtime target Baxalta meeting to talk takeover: Bloomberg

Carly Helfand Shire has refused to give up on target Baxalta, which first rejected it 5 months ago. And its persistence may finally be paying off. FiercePharma News
Page 5 of 7« First...34567
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS